Is methoxydine a new rapid acting antidepressant for the treatment of depression in alcoholics?
Maurizio Coppola, Raffaella Mondola
Medical Hypotheses July 1, 2013 DOI: 10.1016/j.mehy.2013.03.030 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Topics | Depression |
| Key points | Proposes that methoxydine may produce rapid antidepressant effects in depressed patients with high suicide risk, including depressed alcoholics, due to its pharmacodynamic profile. |
Abstract
Methoxydine is a dissociative anaesthetic belonging to the arylcyclohexylamine class. This substance shows pharmacodynamic similarities with ketamine, a medication with demonstrated rapid-acting antidepressant effects. Like ketamine, results of binding assays have shown that methoxydine is an uncompetitive antagonist of NMDA receptor approximately as potent as ketamine, but less potent than PCP. Furthermore, unlike ketamine, it acts as a dopamine, serotonin, and noradrenaline reuptake inhibitor as well as an agonist at sigma-1, sigma-2, and opioid receptors. The hypothesis is that methoxydine can produce rapid antidepressant effects in depressed patients with high risk of suicide, including depressed alcoholics.